Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.607336
Title: An investigation into tetraspanin CD151 as novel prognostic markers in poor outcome endometrial cancer
Author: Voss, Martin August
ISNI:       0000 0004 5363 6889
Awarding Body: University of Birmingham
Current Institution: University of Birmingham
Date of Award: 2014
Availability of Full Text:
Access through EThOS:
Access through Institution:
Abstract:
Background: Type II endometrial carcinoma, sarcoma and carcinosarcoma account for 10% of uterine malignancies but 50% of recurrences. Survival at recurrence is poor and better prognostic markers are needed to guide therapy. The prognostic significance of the novel markers clusterin and tetraspanin CD151 were evaluated in a cohort of poor outcome endometrial malignancies, along with oestrogen receptor, progesterone receptor, p53 and human epidermal growth factor receptor 2. Immunohistochemistry profiles and survival outcome between grade 3 endometroid cancers and type 2 cancers were compared. Material and Methods: Tissue microarrays constructed from 156 poor outcome uterine malignancies, tested with immunohistochemistry and staining were correlated with clinicopathological, mortality and survival data. Results: Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma (USPC+CC) compared to grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma. All other markers were not prognostic for survival. Except for CD151, there was no significant difference in marker positivity, age, stage or survival between G3 EEC and UPSC+CC. Conclusion: CD151 is a novel marker in type 2 cancers that may guide therapeutic decisions. These data also suggest that grade 3 EEC is better characterised as a type II endometrial cancer and may benefit from similar treatment.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.607336  DOI: Not available
Keywords: RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Share: